Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery.
Level 5 - mechanism / opinion, no new human data
Narrative review of drug delivery formulations and mechanisms
PubMed 25987211 · doi:10.1016/j.ijpharm.2015.05.024
What was done
The authors reviewed the therapeutic mechanisms of action, metabolic pathways, and formulation strategies for niacin. The review focuses on conventional oral delivery systems (immediate-release, sustained-release, extended-release), combination products (with statins or prostaglandin receptor antagonists), and emerging strategies such as transdermal patches and polymeric micro- or nanoparticle encapsulation.
What was found
The abstract provides no quantitative data. It reports that while extended- and sustained-release oral formulations alter metabolism to manage hepatotoxicity or flushing, patient compliance remains hindered by prostaglandin-mediated cutaneous flushing. Emerging formulations, including transdermal delivery and micro/nanoparticle encapsulation, show theoretical promise, but their clinical efficacy and safety profiles remain largely unproven.
Why it matters
Understanding how formulation kinetics affect metabolic routing helps guide the engineering of niacin delivery systems that minimize side effects without sacrificing lipid-modulating efficacy.
Limits
This is a narrative review without systematic search criteria or quantitative synthesis. The abstract presents no primary experimental data or clinical trial numbers.
Cited by
- supports High doses of nicotinic acid cause cutaneous flushing and hot-flash-like symptoms.